What happened
Ramiro G. Peru bought 1,000 common shares of Elevance Health, Inc. (NYSE: ELV), adding to the director's personal investment. The purchase put about $384,000 more of Peru's money into the stock, increasing the director's exposure to the same price gains or losses other common shareholders face.
Peru bought the shares in several trades on Nov. 19 at closely grouped prices. The weighted average was $383.86 per share, and individual trades ranged from $383.62 to $383.92. The Form 4 disclosing the trades was dated Nov. 20.
The estimated cost applies to the shares bought that day, not to the value of Peru's full position. The size of that position before the purchase puts the new spending in context.
Explain the financial terms
A Form 4 is the SEC report an officer, director or 10% owner files within two business days of buying or selling the company's stock.
Why it matters
The purchase enlarged an existing stake. OptimistFi calculates that it increased Peru's holding by 9.2% from the 10,908 shares owned immediately before the trades. Peru held 11,908 shares directly after the purchase, so most of the resulting position was already in place.
The filing reports both the purchase and the resulting holding in common shares. The comparison therefore measures how much stock Peru added to the position, rather than how much the position's value changed with the share price.
The multiple trades all came from the same director's purchase on a single day. That distinction matters when looking for a pattern of insider buying. The trades establish that Peru added to a holding, not that other directors or officers are buying alongside Peru.
OptimistFi has argued that durable earnings and cash depend on whether Elevance Health can control benefit expense while collecting premium and fee revenue. The purchase leaves that view unchanged because the size of a director's stake gives investors a measure of personal exposure, not a measure of benefit expense.
What's next
The next quarterly report is the operating test: a lower share of revenue going to benefit expense would support OptimistFi's view, while a higher share would weaken it.

